With the growth of the market for organic products, four of the top five medicines sold in the world are delivered by injection. Because these drugs are complex, biologicals often require robust design efforts and current delivery challenges.
"There is a challenge with how best to deal with high-volume injections and highly viscous biological drugs," says Terence O'Hagan, General Manager of Haselmeier, Inc.
In general, in the biotechnology sector, the 1 ml needle syringe is the most commonly used format for subcutaneous injections, explains Claudia Petersen, Global Director of Business Development at Gerresheimer Bünde GmbH. "But the trend towards higher dosage volumes brings with it an increasing demand for syringes of 2.25 ml of needle."
In addition, with the emergence of biological products, portable devices are in high demand, "says Mark Hassett, vice president of sales and business development at Medipacs, Inc." In fact, the market for devices to address these next-generation biological products, volume injection capabilities is estimated to be between $ 7 and $ 10 billion over the next 5 years. "